Genentech Says It Shouldn't Lose Patent Rights Over Error

Law360, London (March 26, 2020, 11:12 PM GMT) -- Genentech urged the Court of Appeal on Thursday to overlook a mistake made by one of its agents that threatens to prematurely end certain patent rights it has for its eye-disease treatment.

The biotechnology company is fighting to extend what's known as a supplementary protection certificate, or SPC, for an antibody marketed under the brand name Lucentis used to treat an eye disorder called wet age-related macular degeneration.

The SPC came into force in April 2018, a day after the basic patent for the product expired. According to court documents, a company tasked by Genentech to pay the annual fees for...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!